Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|January 23, 2025

Abiraterone Acetate Versions for Treatment of mCRPC

Author(s)Jose De La Cerda III, MD, MPH

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.

Episodes in this series

EP. 1 Bone Predominant mCRPC Patient Case

EP. 1 Bone Predominant mCRPC Patient Case

EP. 2 Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP. 2 Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP. 3 Abiraterone Acetate Versions for Treatment of mCRPC

EP. 3 Abiraterone Acetate Versions for Treatment of mCRPC

EP. 4 Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP. 4 Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP. 5 Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP. 5 Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP. 6 Patient with mCRPC and Hepatic Disease

EP. 6 Patient with mCRPC and Hepatic Disease

EP. 7 Treatment and Co-Management of mCRPC Patients with Aggressive Disease

EP. 7 Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Video content above is prompted by the following:

Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Treatment Patterns in Advanced Prostate Cancer from Monotherapy to Treatment Intensification

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

February 4th 2026

Interpreting PSMA PET Imaging in Prostate Cancer

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

February 4th 2026

Strategic Use of ADT in mCSPC From Selection to Escalation

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

January 27th 2026

Treatment Selection in Advanced Prostate Cancer

ByPaul Sieber, MD,Alicia Morgans, MD, MPH,Chad Ritch, MD, MBA,Neeraj Agarwal, MD, FASCO

January 27th 2026

Advice for the Next Generation of Urologists in mCSPC Management

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

January 27th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD

FDA approves sildenafil oral film for men with erectile dysfunction

Sarah Azari, MD, on early sexual health education for women with bladder cancer

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC